Literature DB >> 32622478

Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic review.

Mike Fruscione1, Ryan C Pickens1, Erin H Baker1, John B Martinie1, David A Iannitti1, Jimmy J Hwang2, Dionisios Vrochides3.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a devastating malignant neoplasm with dismal outcomes. Several therapeutic modalities have been used with variable success to downsize these tumors for resection. Neoadjuvant therapy such as chemoembolization and radioembolization offer promising options to manage tumor burden prior to resection. A systematic review of the literature was performed with a focus on conversion therapy for ICC and tumor downsizing to increase resection rates among patients who have an initially unresectable tumor. Of 132 patients with initially unresectable ICC, we identified 27 who underwent conversion therapy with surgical resection. Adequate tumor downsizing was achieved with chemotherapy, chemoembolization, radioembolization, or combination thereof. Although negative tumor margins were possible in some patients, recurrence rates and survival outcomes were inconsistently reported. Twenty-three of 27 patients were alive at last reported follow-up. Conversion therapy for initially unresectable ICC may offer adequate tumor downsizing for resection.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemoembolization; Cholangiocarcinoma; Conversion therapy; Liver neoplasms; Neoadjuvant therapy

Mesh:

Substances:

Year:  2020        PMID: 32622478     DOI: 10.1016/j.currproblcancer.2020.100614

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN: 0147-0272            Impact factor:   3.187


  7 in total

1.  A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma.

Authors:  Yuma Wada; Mitsuo Shimada; Yuji Morine; Tetsuya Ikemoto; Yu Saito; Hideo Baba; Masaki Mori; Ajay Goel
Journal:  Br J Cancer       Date:  2022-01-25       Impact factor: 9.075

2.  Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection.

Authors:  Joshua S Jolissaint; Kevin C Soares; Kenneth P Seier; Ritika Kundra; Mithat Gönen; Paul J Shin; Thomas Boerner; Carlie Sigel; Ramyasree Madupuri; Efsevia Vakiani; Andrea Cercek; James J Harding; Nancy E Kemeny; Louise C Connell; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; T Peter Kingham; Alice C Wei; William R Jarnagin
Journal:  Clin Cancer Res       Date:  2021-05-07       Impact factor: 12.531

3.  Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study.

Authors:  Qiyi Zhang; Xingyu Liu; Shumei Wei; Lufei Zhang; Yang Tian; Zhenzhen Gao; Ming Jin; Sheng Yan
Journal:  Front Oncol       Date:  2021-11-24       Impact factor: 6.244

4.  Systemic Therapy Is Associated with Improved Oncologic Outcomes in Resectable Stage II/III Intrahepatic Cholangiocarcinoma: An Examination of the National Cancer Database over the Past Decade.

Authors:  Rebecca Marcus; Wade Christopher; Jennifer Keller; Sean Nassoiy; Shu-Ching Chang; Melanie Goldfarb; Ronald Wolf; Zeljka Jutric
Journal:  Cancers (Basel)       Date:  2022-09-03       Impact factor: 6.575

Review 5.  Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma.

Authors:  Clifford Akateh; Aslam M Ejaz; Timothy Michael Pawlik; Jordan M Cloyd
Journal:  World J Hepatol       Date:  2020-10-27

6.  Conversion Therapy of Intrahepatic Cholangiocarcinoma Is Associated with Improved Prognosis and Verified by a Case of Patient-Derived Organoid.

Authors:  Zhiwei Wang; Yun Jin; Yinghao Guo; Zhenhua Tan; Xiaoxiao Zhang; Dan Ye; Yuanquan Yu; Shuyou Peng; Lei Zheng; Jiangtao Li
Journal:  Cancers (Basel)       Date:  2021-03-09       Impact factor: 6.639

7.  Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.

Authors:  Ze Zhang; Wenwen Zhang; Hongguang Wang; Bingyang Hu; Zhanbo Wang; Shichun Lu
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.